Myofascial Techniques and Proprioceptive Neuromuscular Facilitation in Patients With Systemic Lupus Erythematosus.

March 24, 2025 updated by: Rubén Cuesta-Barriuso, PhD, Universidad Católica San Antonio de Murcia

Combination of Myofascial Techniques and Proprioceptive Neuromuscular Facilitation in the Clinical and Functional Improvement of Patients With Systemic Lupus Erythematosus. Randomised Clinical Study

Introduction. Systemic lupus erythematosus is an autoimmune disease. The musculoskeletal system is affected in 90% of patients. The most common manifestations are myalgias, arthralgias and arthritis.

Objective. To analyse the efficacy of an intervention using myofascial techniques and proprioceptive neuromuscular facilitation in patients with systemic lupus erythematosus.

Methods. Randomised clinical study with 20 patients with systemic lupus erythematosus, randomised to an experimental and control group. The intervention will last 4 weeks, with a periodicity of 2 weekly sessions of 50 minutes each. The intervention of the experimental group will consist of a protocol using myofascial and proprioceptive neuromuscular facilitation techniques.

Expected results. Improvement of knee and ankle pain intensity, functional capacity, basic mobility skills, strength, balance, agility and fatigue.

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

17

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Murcia, Spain, 30107
        • Universidad Católica San Antonio, Murcia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Subjects over 18 years of age
  • With a medical diagnosis of systemic lupus erythematosus
  • Who sign the informed consent form.

Exclusion Criteria:

  • Patients with fever or acute phlebitis.
  • Patients with recent lower limb fractures
  • Amputees and people with neurological or cognitive impairments that prevent them from correctly understanding the questionnaires and performing the guided techniques.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Experimental group
The intervention period will last 4 weeks, with a periodicity of 2 weekly sessions of 50 minutes each. The intervention of the experimental group will consist of a protocol using myofascial and proprioceptive neuromuscular facilitation techniques.
Three myofascial release techniques will be performed with low load and long duration stretching to the myofascial complex to restore optimal length, decrease pain and improve function. In the development of the deep myofascial techniques, respiratory synchronisation with the patient will be performed. Proprioceptive neuromuscular facilitation techniques will be performed by executing diagonal spiral movements against resistance, several times, through a full range of motion. Three sets of three repetitions with 6-second contractions and a 30-second rest between sets shall be performed.
No Intervention: Control group
Patients included in the control group will not receive any intervention, maintaining their activities of daily living in the same way as before the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline joint pain after treatment and at 4 weeks
Time Frame: Screening visit, within the first seven days after treatment and after four weeks follow-up visit
The intensity of knee and ankle pain shall be measured with the visual analogue scale. This instrument has an excellent test-retest reliability. This measurement scale consists of an unnumbered 10 cm line, where the patient is asked to indicate the perception of pain in the knee and ankle joints in the last week. The scale ranges from 0 to 10, where 0 indicates no pain at all and 10 indicates maximum perceived pain.
Screening visit, within the first seven days after treatment and after four weeks follow-up visit

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline functional capacity after treatment and at 4 weeks
Time Frame: Screening visit, within the first seven days after treatment and after four weeks follow-up visit
Functionality of the lower limbs will be measured with the 2-Minute Walking Test. Functional capacity to exercise will be assessed by this modified version of the 6-minute version. This instrument has shown excellent test-retest reliability. This test will be performed in a closed corridor, with a length of 30 m delimited between cones. Subsequently, they shall be instructed to walk around the circuit around the cones as fast as possible, but without running, for 2 minutes. The distance covered at the end of the 2 minutes, in metres, shall be recorded by the assessor.
Screening visit, within the first seven days after treatment and after four weeks follow-up visit
Change from baseline functionality after treatment and at 4 weeks
Time Frame: Screening visit, within the first seven days after treatment and after four weeks follow-up visit
The Timed Up and Go Functionality Test will assess basic mobility skills, strength, balance and agility. This instrument can help predict an individual's risk of falls and other adverse outcomes. This test has shown excellent intra-rater reliability. This test measures the time it takes a patient to get up from an armchair (without using the arms to get up), walk to a line on the floor 3 m away, turn around, and return to the chair and sit down. The unit of measurement is seconds
Screening visit, within the first seven days after treatment and after four weeks follow-up visit
Change from baseline joint pain after treatment and at 4 weeks
Time Frame: Screening visit, within the first seven days after treatment and after four weeks follow-up visit
Fatigue will be assessed using the Fatigue Assessment Scale. This scale provides information on physical and psychological aspects of fatigue. The reliability of this scale is high. This instrument is a self-report questionnaire consisting of 10 items with a 5-point Likert response scale ranging from "1=never to "5=Always". Five items reflect the physical component and five reflect the psychological component. The score range of the scale is 10-50, where the higher the score, the greater the degree of fatigue.
Screening visit, within the first seven days after treatment and after four weeks follow-up visit

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 22, 2024

Primary Completion (Actual)

May 28, 2024

Study Completion (Actual)

June 26, 2024

Study Registration Dates

First Submitted

April 18, 2024

First Submitted That Met QC Criteria

April 18, 2024

First Posted (Actual)

April 25, 2024

Study Record Updates

Last Update Posted (Actual)

March 27, 2025

Last Update Submitted That Met QC Criteria

March 24, 2025

Last Verified

April 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe